-
Palmitic acid: Protocol and QC Guide
2026-08-31
Palmitic acid (hexadecanoic acid, SKU N2456) provides a defined saturated long-chain fatty acid input for studies of lipid metabolism, insulin signaling, inflammation, and protein palmitoylation. It is unsuitable for aqueous-only protocols and should be prepared in a compatible organic solvent, used promptly, and stored as a sealed solid at -20°C.
-
MHY1485: A Mechanistic mTOR–Autophagy Guide
2026-08-30
MHY1485 is an mTOR activator that also disrupts autophagosome–lysosome fusion. This mechanism-first guide connects pathway biology from an EBV–NPC study to rigorous autophagy assay design, translational interpretation, and ovarian follicle development research.
-
PPARγ Activation in DSS-Induced IBD
2026-08-29
The reference study shows that pioglitazone-mediated PPARγ activation reduces DSS-induced intestinal inflammation by shifting macrophage polarization away from an M1-dominant state and toward an M2-associated profile. Its combined cell and mouse experiments connect these changes to opposing effects on STAT-1 and STAT-6 phosphorylation, providing a useful framework for studying inflammatory process modulation.
-
Cediranib (AZD2171): Beyond Viability
2026-08-28
Cediranib (AZD2171) is an angiogenesis inhibitor whose pathway effects can be obscured by conventional viability assays. This guide integrates VEGFR biology with a two-axis framework for separating growth inhibition from cell killing in cancer research.
-
KX2-391 Dihydrochloride: Assay Workflows
2026-08-28
KX2-391 dihydrochloride supports integrated oncology, HBV, and BoNT/A workflows by combining substrate-site Src inhibition with disruption of tubulin polymerization. This guide translates reported potency ranges into practical assay setup, controls, troubleshooting steps, and mechanism-aware interpretation.
-
JNJ-26481585: An Assay Strategy for HDAC Biology
2026-08-27
JNJ-26481585 (Quisinostat) is a potent epigenetic modulator for connecting HDAC inhibition with apoptosis, proliferation, and drug resistance. This guide translates recent TRIM21–ERK1/2 findings into a rigorous, multi-readout assay strategy rather than treating viability as a standalone endpoint.
-
Olsalazine Sodium: Research Workflows
2026-08-27
Olsalazine Sodium connects LTB4-driven inflammation assays with colorectal cancer tumor models and emerging mosquito xenobiotic-transport workflows. This practical guide covers aqueous formulation, dose selection, paired molecular and physiological readouts, and troubleshooting for reproducible experiments.
-
PFOS Injury in HK-2 Cells: Ferroptosis and ER Stress
2026-08-26
The reference study shows that perfluorooctane sulfonate (PFOS) injures human proximal tubular HK-2 cells through coordinated ferroptosis-associated changes and activation of the endoplasmic reticulum stress pathway. By combining renal injury, lipid peroxidation, iron, antioxidant, and unfolded protein response markers, the work provides a mechanistic framework for studying persistent chemical toxicity in kidney cells.
-
BMS-777607 in hiPSC Platelet Research
2026-08-26
BMS-777607 is a selective c-Met inhibitor that can be used to interrogate MET-family signaling in hiPSC-derived megakaryocyte and platelet workflows. This guide connects target-validation assays, metastasis models, and differentiation optimization while distinguishing established findings from practical pilot recommendations.
-
Hypoxia, TXNIP, and NLRP3 in Urothelial Cells
2026-08-25
The reference study shows that enzyme-induced hypoxia activates inflammatory signaling in urothelial cells in a duration-dependent manner. Its results support a ROS-linked TXNIP/NLRP3 mechanism and identify Verapamil as a pharmacological probe for testing this pathway, while also highlighting the limitations of interpreting caspase-1 activity as complete inflammasome confirmation.
-
JNJ-26481585 (Quisinostat) Workflow Guide
2026-08-25
JNJ-26481585 (Quisinostat) combines potent class I HDAC inhibition with practical readouts for apoptosis, epigenetic target engagement, and drug resistance. This workflow guide connects TRIM21–ERK1/2 biology in pituitary adenoma models with reproducible cell-based, mechanistic, and tumor growth inhibition studies.
-
GW 6471: PPARα Antagonist Research Guide
2026-08-24
GW 6471 is a small-molecule PPARα antagonist for dissecting PPARα-dependent transcription in cellular metabolism research. Its reported IC50 is approximately 0.24 μM, while zebrafish evidence supports pharmacological PPAR pathway interrogation in PFHxS-induced hepatotoxicity.
-
SINAT–VAB1 Control of Autophagy in Arabidopsis
2026-08-24
The reference study identifies VAB1, a V-ATPase subunit, as a SINAT-associated regulator of autophagic vesicle degradation in Arabidopsis. Its findings connect SINAT-dependent ubiquitination and turnover of VAB1 with vacuolar acidification, nutrient-starvation tolerance, and premature leaf senescence.
-
PRDX6–GPX4 Control of Ferroptosis
2026-08-23
Hu et al. identify PRDX6 as a dual regulator of ferroptosis resistance: it hydrolyzes peroxidized phospholipids and enables GPX4 recruitment to damaged membranes through disulfide-dependent binding. The study links this mechanism to tumor suppression and supports combined PRDX6 inhibition and ferroptosis induction as a strategy for overcoming lipid-peroxidation resistance.
-
Humanized Mice Clarify HD56 Prodrug Disposition
2026-08-22
The 2025 reference study shows that humanized-liver mice can resolve species-dependent metabolism of the carboxylate ester prodrug HD56 and improve in vivo–in vitro correlation. Its combined transport, enzyme-phenotyping, microsomal, plasma, and pharmacokinetic strategy offers a practical framework for evaluating ester prodrugs before clinical development.